Anonymous
Guest
Anonymous
Guest
http://blogs.wsj.com/source/2011/07/21/astrazeneca-too-few-eggs-too-small-a-basket/?mod=yahoo_hs
So much for what the investment community thinks of Brilinta. Here's an excerpt from the article:
Opinions vary widely over what impact the warning will have on Brilinta’s launch in the U.S., as seen from just three broker note headlines Thursday:
“The label, in our view, is less competitive than AZN would have liked” – Matrix
“Pyrrhic victory for Brilinta, slow U.S. launch expected” – Jefferies
“Brilinta FDA approval should drive consensus upgrades” – MF Global
So much for what the investment community thinks of Brilinta. Here's an excerpt from the article:
Opinions vary widely over what impact the warning will have on Brilinta’s launch in the U.S., as seen from just three broker note headlines Thursday:
“The label, in our view, is less competitive than AZN would have liked” – Matrix
“Pyrrhic victory for Brilinta, slow U.S. launch expected” – Jefferies
“Brilinta FDA approval should drive consensus upgrades” – MF Global